Skip to main
SLDB

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences is a promising investment opportunity due to continued progress in their gene therapy portfolio, particularly with their current lead candidate SGT-003 for the treatment of Duchenne muscular dystrophy, as well as potential treatments for other genetic diseases. The company has a strong cash position and positive interactions with the FDA, indicating a potential accelerated approval pathway for SGT-003. With a diverse and innovative platform and ongoing Phase 3 trials, Solid Biosciences remains a top pick for longer-term investors.

Bears say

Solid Biosciences is a life sciences company that operates in a single segment, developing treatments for neuromuscular and cardiac diseases through gene therapy and other means. However, the company has faced challenges, reporting a loss in the first quarter despite having a strong cash position and expecting to have enough funds through 2028. Additionally, the company's success in the market is dependent on its ability to execute commercially and navigate competition from other players in the field, making it a risky investment option.

Solid Biosciences (SLDB) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 11 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.